Spironolactone, given what‘s known about its effects on the body, has been considered as a possible candidate to treat at least some conditions associated with COVID-19. But the drug is untested in clinical trials.
Spironolactone is anti-inflammatory and anti-fibrotic, potentially making it useful against pulmonary complications of COVID-19 such as pulmonary fibrosis. Preliminary theories posit that the drug could mitigate risk factors like hypertension and androgen exposure and provide protection from the virus.